COVID-19 Death and BCG Vaccination Programs Worldwide

Several clinical trials are being conducted worldwide to investigate the protective effect of the bacillus Calmette-Guérin (BCG) vaccine against death in healthcare providers who are working directly with coronavirus disease 2019 (COVID-19) patients. Clinical studies suggested that certain live vaccines, particularly the BCG vaccine, could reduce the mortality due to other diseases caused by non-targeted pathogens, most probably through the nonspecific effects (heterologous effects). By the end of May 2020, the available information on the COVID-19 pandemic indicated the great effect of the BCG vaccine in reducing the number of COVID-19 death cases. The occurrence of death due to COVID-19 was found to be 21-fold lower in countries with a national BCG vaccination policy than in countries without such a policy, based on the medians of COVID-19 death case per 1 million of the population in these two groups of countries (p<0.001, MannWhitney test). Therefore, it can be concluded that the early establishment of a BCG vaccination policy in any country is a key element in reducing the number of COVID-19 and tuberculosis death cases.

Media Type:

Electronic Article

Year of Publication:

2021

Contained In:

Tuberculosis and respiratory diseases - Vol. 84, No. 1 (2021), p. 13-21

Language:

English

Contributors:

Jirjees, Feras J
Dallal Bashi, Yahya H
Al-Obaidi, Hala J

Links:

Volltext

Keywords:

BCG Vaccine
COVID-19 Death Cases
COVID-19 Mortality
COVID-19 Pandemic
Coronavirus
Journal Article

Notes:

Date Revised 08.01.2021

published: Print-Electronic

Citation Status PubMed-not-MEDLINE

Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Physical Description:

Online-Ressource

doi:

10.4046/trd.2020.0063

PMID:

32883062

PPN (Catalogue-ID):

NLM315505486